- Approximately one-third of women in Dubai and Abu Dhabi report postpartum depression symptoms at six months postpartum, yet the UAE lacks robust screening and referral pathways, meaning many mothers are managing this alone (European Journal of Midwifery, 2024).
- Sertraline and paroxetine are identified by the NHS Specialist Pharmacy Service as the SSRIs of choice during breastfeeding, with very low milk transfer and infant plasma levels that are typically undetectable in studies.
- The risk of leaving postnatal depression untreated is not zero: systematic review evidence links untreated maternal depression to higher rates of insecure infant attachment and worse developmental outcomes in the first year of life.
- In Dubai, antidepressants for postnatal depression must be prescribed by a DHA-licensed psychiatrist; SSRIs such as sertraline are prescription-only medicines and are not controlled substances requiring special permits.
- CBT-based therapy at CAYA World can be used alongside medication or as a standalone treatment for mild-to-moderate postnatal depression, giving mothers a structured, evidence-based option that does not involve infant medication exposure.
A 2024 scoping review published in the European Journal of Midwifery found that approximately one-third of women in Dubai and Abu Dhabi report postpartum depression symptoms at six months postpartum, yet the same review concluded that the UAE lacks robust screening and referral pathways for perinatal mental health. Many of those mothers are also breastfeeding. And many of them are quietly asking the same question: do I have to choose between my mental health and feeding my baby?
The short answer is: usually not. But the longer answer matters, because the decision about breastfeeding and antidepressants in Dubai is not one-size-fits-all. It depends on the specific medication, the severity of depression, infant age, and a clinical conversation that most mothers in this region are not yet having with a qualified prescriber.
This article is designed to help you arrive at that conversation better informed. At CAYA World, we work with mothers experiencing postnatal depression in our therapy room every week. We do not prescribe medication, but we do understand the evidence, and we see firsthand how much clarity helps. Our goal here is to lay out the clinical picture clearly, so that you can ask the right questions of your DHA-licensed psychiatrist.
Is it safe to take antidepressants while breastfeeding?
The phrase "safe" does a lot of heavy lifting in this conversation, and it is worth unpacking precisely. No medication passes zero percent into breast milk. The clinical question is always whether the amount that does transfer is clinically significant, and what the consequences of that exposure are compared with the consequences of the mother remaining unwell.
For the most commonly prescribed antidepressants during the postnatal period, the answer from current evidence is reassuring. A 2021 meta-analysis by Uguz, published on PubMed, found that sertraline and paroxetine produce very low or usually undetectable infant serum levels during breastfeeding, and concluded that routine serum sampling is not warranted for mothers or infants on sertraline monotherapy. The NHS Specialist Pharmacy Service (2024) reaches the same conclusion, identifying sertraline and paroxetine as the selective serotonin reuptake inhibitors (SSRIs) of choice during breastfeeding on the grounds of low milk transfer and very low infant plasma levels.
This does not mean that all antidepressants carry the same profile. Fluoxetine, for instance, has a much longer half-life and active metabolites that accumulate differently in infant plasma. Some older tricyclic antidepressants also carry a different evidence base. The medication class and the specific compound both matter. That is exactly why the decision belongs with a prescribing psychiatrist who can review your full clinical picture, not a general reassurance from any single source, including this one.
What the evidence consistently shows is that the framing of "antidepressants are dangerous while breastfeeding" is not supported by the data for the most commonly used first-line SSRIs. The clinical community has moved away from automatic either-or recommendations. Organisations including the World Health Organization and the American Psychiatric Association (APA) now advocate for a risk-benefit framework: weigh the evidence on infant exposure against the well-documented risks of leaving maternal depression untreated.
At CAYA World, we frequently hear mothers say they stopped medication abruptly after delivery because they assumed breastfeeding made it impossible to continue. Some were not told otherwise. Stopping suddenly can trigger discontinuation effects and destabilise mental health at one of the most demanding times in a person's life. If you are in this position, speaking to a psychiatrist and a therapist before making any changes is the most clinically grounded step you can take.
Which antidepressants are considered safest for breastfeeding mothers?
Evidence-based guidance consistently places sertraline and paroxetine at the top of the safety hierarchy for breastfeeding mothers who need antidepressant treatment. The table below summarises the current evidence picture for the SSRIs most commonly encountered in postnatal care. This is for informational purposes only. Medication decisions must be made with a licensed prescriber who knows your individual history.
| SSRI | Relative milk transfer | Typical infant plasma levels | Current guidance position |
|---|---|---|---|
| Sertraline | Low | Undetectable or very low in most studies | First-line choice; extensive evidence base (NHS SPS, 2024) |
| Paroxetine | Low | Undetectable in most infant samples | First-line choice alongside sertraline (NHS SPS, 2024) |
| Escitalopram / Citalopram | Moderate | Detectable but generally low; monitor infant for sedation | May be considered; less preferred than sertraline as first-line |
| Fluoxetine | Moderate to higher | Detectable, including active metabolite norfluoxetine; accumulation risk in neonates | Generally avoid initiating in breastfeeding; review if already established |
The evidence base for sertraline is particularly extensive because it has been the most studied SSRI in breastfeeding populations. Uguz's 2021 meta-analysis reviewed multiple studies and found that infant serum levels were undetectable in the majority of cases. The mechanism is straightforward: sertraline is highly protein-bound and has a relatively short half-life compared to fluoxetine, which limits how much crosses into milk and how much an infant can absorb from that milk.
Paroxetine shares a similarly favourable profile. However, paroxetine carries a higher risk of discontinuation syndrome in adults if doses are missed, which is a relevant practical consideration for a new mother whose schedule is unpredictable. A psychiatrist will factor this into the prescribing decision.
What about non-SSRI antidepressants? Some SNRIs (serotonin-norepinephrine reuptake inhibitors) have emerging safety data in breastfeeding, and some older medications such as nortriptyline and imipramine have been used for decades with reasonable data. These are outside the scope of a general informational article. The point is that the pharmacological landscape is more nuanced than "antidepressants are safe" or "antidepressants are dangerous." Your prescriber will match the medication to your history, prior treatment response, and your infant's age and health.
One practical note: infants who are premature, have low birth weight, or have any cardiac or hepatic conditions are assessed differently. A neonatologist or paediatrician may be involved in the monitoring plan. This is not cause for alarm. It is simply good clinical practice.
What is the risk of leaving postnatal depression untreated?
This is the part of the conversation that often gets omitted. When mothers ask about antidepressant safety for their baby, the comparison point is not "medication versus nothing." The comparison point is "medication versus untreated postnatal depression", and untreated postnatal depression carries its own substantial evidence-based risks, for both mother and infant.
Globally, approximately 13% of women experience a mental disorder, primarily depression, after childbirth. That figure rises to approximately 19.8% in lower-income settings, according to WHO perinatal mental health data (2024). In Dubai specifically, the picture is stark: the UAE scoping review published in the European Journal of Midwifery (2024) found that approximately one-third of women in Dubai and Abu Dhabi reported postpartum depression symptoms at six months postpartum.
The infant-development evidence on untreated maternal depression is sobering. A systematic review published in PMC found that most studies examining infant attachment in the context of untreated postnatal depression found a raised rate of insecure attachment; infants of postnatally depressed mothers also showed worse developmental outcomes and more mild behavioural difficulties. These effects are not inevitable, and they are not the mother's fault. But they are clinically real, and they are part of the risk equation that prescribers weigh when recommending treatment.
There is also a UAE-specific data point that runs in the opposite direction to the common worry. A 2023 cohort study published in PMC found that breastfeeding itself was associated with a lower likelihood of postpartum depressive symptoms over the first six months postpartum. This matters because it means supporting a mother to continue breastfeeding, including through safe medication use where indicated, may itself be a protective factor for her mental health.
The clinical logic here is important to state plainly. A mother who is severely depressed, unable to respond to her baby's cues, sleeping irregularly, experiencing significant anxiety or intrusive thoughts, and struggling to engage with day-to-day care is not in a position to give her baby the sensitive caregiving that supports secure attachment. Treating that depression, whether through medication, therapy, or both, directly supports the mother-infant relationship. The decision is not medication or baby. It is often: treat the mother effectively so that she and her baby can thrive together.
If you are unsure whether what you are experiencing is postnatal depression or something less acute, our article on postpartum depression versus baby blues in Dubai covers the distinction in detail, including when professional assessment is the appropriate next step.
At CAYA World, we offer postpartum therapy and support for mothers working through this period, whether they are also receiving medication from a psychiatrist or approaching treatment through therapy alone. If you are finding it hard to know where to start, a brief intake conversation with our team is a low-pressure first step.
How to navigate antidepressants and breastfeeding in Dubai
Knowing the evidence is one thing. Knowing how the healthcare system actually works in Dubai is another. Mothers in the UAE face a prescribing pathway that differs from what many expats are familiar with from the UK, US, Australia, or Europe, and understanding it reduces delays and confusion.
In Dubai, antidepressants including SSRIs must be prescribed by a DHA-licensed psychiatrist. A general practitioner or obstetrician may screen for postnatal depression, and many do, but they cannot prescribe most antidepressants independently. SSRIs such as sertraline are prescription-only medicines in the UAE but are not classified as controlled substances under DHA's narcotics and psychotropics framework, which means they do not require the special red-prescription process used for medications like benzodiazepines. A DHA-licensed psychiatrist can prescribe SSRIs for up to 90 days under DHA's prescribing circular framework, and prescriptions can be filled at most licensed UAE pharmacies.
The practical pathway for most mothers looks like this:
- Speak to your GP or obstetrician about your symptoms and request a referral to a DHA-licensed psychiatrist.
- Contact your health insurance provider to confirm whether outpatient psychiatry is covered under your plan, and whether a GP referral is required to unlock the benefit.
- At your psychiatry appointment, discuss your breastfeeding status explicitly, including your infant's age and any relevant health history. Your psychiatrist will factor this into the prescribing decision.
- If medication is prescribed, ask your psychiatrist about infant monitoring, what symptoms to watch for in your baby, whether any dose timing adjustments are recommended, and when a follow-up appointment is needed.
- Consider parallel psychological support. Medication addresses the neurobiological dimension of depression; structured therapy addresses the cognitive, behavioural, and relational patterns that often accompany it and can sustain recovery after medication is tapered.
Questions worth raising with your prescribing psychiatrist include: which specific medication they recommend and why, what the evidence base is for that choice during breastfeeding, what the plan is if you or your baby experience side effects, and how long the course is expected to last. A good psychiatrist will welcome these questions. If you feel rushed or unheard, seeking a second opinion is reasonable clinical behaviour, not a sign of being difficult.
For a broader picture of postnatal mental health services available in Dubai, including non-medication support routes, our article on postnatal mental health in Dubai provides a useful orientation to the landscape.
Wondering if It's Time to Talk to Someone?
Our specialist team at CAYA World offers comprehensive assessment and evidence-based treatment, conducted from our clinic in Palm Jumeirah, Dubai.
Cultural pressures and the stigma Dubai mothers face around medication
Dubai's population is extraordinarily diverse, but many of the mothers we work with at CAYA World share a common experience regardless of nationality: the feeling that taking antidepressants is something to be ashamed of, hidden from family, or associated with a level of psychiatric illness that does not reflect their situation.
Research across Arab and MENA populations consistently documents beliefs that antidepressants are addictive, that they signify severe mental illness, or that seeking psychiatric medication is a sign of weak faith or poor character. These beliefs are not confined to any one community. Similar stigma patterns appear in South Asian, East Asian, and many Western expat communities in the Gulf. PMC research conducted with UAE populations in 2023 found that many women turn to family or religious support before engaging professional mental health care, and that concerns about confidentiality and social judgment are significant barriers to treatment-seeking.
Expat mothers face an additional layer of complexity. They may be navigating new motherhood without the extended family networks that would normally provide support. They may have limited experience with the UAE healthcare system and uncertainty about whether their mental health history is recorded in a way that affects insurance, visa status, or employment. To be clear: postnatal depression is a medical condition, not a character flaw, and accessing psychiatric treatment in a DHA-licensed clinical setting is confidential clinical care. It does not appear on visa records.
The practical consequence of stigma is delay. Mothers who feel that medication means something negative about them tend to wait longer before seeking help, and the longer postnatal depression goes untreated, the more entrenched the neurobiological and behavioural patterns become. A mother who might have responded well to a short course of therapy and/or a three-month SSRI prescription in the early weeks postpartum may, six months later, require a more intensive intervention.
At CAYA World, we do not frame medication as a weakness or a last resort. We also do not frame it as the only valid response. We work with mothers across the full spectrum: those who choose medication, those who prefer therapy alone, and those combining both. The goal is always to get you back to functioning, engaging, and feeling present for yourself and your baby, through whatever evidence-based route fits your clinical picture and your values.
How therapy supports you alongside or instead of medication
For many mothers, the decision about medication is made easier when they understand that effective treatment options exist that do not involve any compound entering breast milk. Psychological therapy, particularly cognitive behavioural therapy (CBT), has a strong and well-replicated evidence base for postnatal depression and is recommended by both the APA and NICE (National Institute for Health and Care Excellence) as a first-line treatment for mild-to-moderate postnatal depression.
CBT for postnatal depression works by helping you identify the thought patterns and behavioural cycles that maintain low mood. New mothers are particularly vulnerable to patterns of self-criticism, catastrophic thinking about infant safety, guilt about not enjoying motherhood, and social withdrawal, all of which CBT directly addresses. Sessions typically run weekly, each lasting 50 minutes, and a structured course for postnatal depression generally spans 12 to 20 sessions depending on severity and presentation.
In practice, many mothers at CAYA World use therapy in combination with medication prescribed by a psychiatrist. The two approaches are complementary. Medication can lift the floor quickly, reducing the intensity of depressive symptoms enough that a mother can engage productively in therapy. Therapy builds the skills and cognitive patterns that sustain recovery and reduce relapse risk after medication is tapered. This is not CAYA World committing to any framework beyond CBT; it is the standard clinical model supported by the evidence base for perinatal depression.
For mothers with mild-to-moderate postnatal depression, therapy alone is often sufficient. The decision about whether to add medication is made jointly with a psychiatrist, ideally with input from the therapist who is seeing you regularly and can observe your week-to-week functioning. This kind of coordinated care, where your psychologist and psychiatrist communicate, is the clinical gold standard and is available in Dubai's private healthcare sector.
Practical considerations for Dubai mothers in therapy include the logistics of attending weekly sessions with a newborn. At CAYA World, our clinical team is experienced in accommodating the unpredictability of new parenthood, and our Palm Jumeirah location is accessible from most residential areas of Dubai. Sessions can also be conducted via secure video call for mothers who cannot travel.
If you have been uncertain about whether what you are experiencing warrants professional support, or if you have been managing symptoms quietly while telling yourself you should be coping better, this is the moment to reach out. You do not need to be in crisis to benefit from structured support. Many mothers who come to CAYA World describe their experience as finally being heard by someone who understands the clinical picture, and who can help them make a genuinely informed decision about next steps.
Our postpartum therapy and support service is designed for exactly this situation. A first appointment is not a commitment to a particular treatment plan. It is a confidential clinical conversation that helps you understand your options and make decisions from a position of information rather than fear. If you would also like to explore the role of therapy for depression more broadly, our depression therapy service page outlines the CBT-based approaches we use at CAYA World.
Frequently Asked Questions About Breastfeeding and Antidepressants in Dubai
Yes, in most cases. Both sertraline and paroxetine are identified by the NHS Specialist Pharmacy Service (2024) as the SSRIs of choice during breastfeeding, based on evidence showing very low milk transfer and typically undetectable infant plasma levels. A 2021 meta-analysis found that routine serum monitoring is not warranted for infants of mothers on sertraline monotherapy. Your psychiatrist will review your specific situation, including your infant's age and health, before confirming any medication decision.
For the SSRIs most commonly prescribed in postnatal care, particularly sertraline and paroxetine, current evidence shows that the amount transferring into breast milk is small and that infant plasma levels are typically undetectable or very low. Serious adverse events in infants of mothers taking these SSRIs at therapeutic doses are rare in the published literature. Older SSRIs such as fluoxetine have a different profile due to longer half-life and active metabolites, and are generally avoided when initiating treatment in breastfeeding mothers. Discuss the specific medication with your prescribing psychiatrist, who can explain the evidence for that compound.
Untreated postnatal depression carries documented risks for both mother and infant. A systematic review found raised rates of insecure infant attachment and worse developmental outcomes in infants of postnatally depressed mothers. For the mother, untreated depression can become more entrenched over time, increasing the duration and intensity of treatment needed later. The clinical decision about whether to treat, and how, always involves weighing these risks against the evidence on medication exposure. Choosing not to treat is also a decision with consequences, and those consequences deserve the same honest clinical assessment.
In Dubai, antidepressants must be prescribed by a DHA-licensed psychiatrist. Your GP or obstetrician may screen for postnatal depression and provide a referral, but general practitioners cannot independently prescribe most antidepressants in the UAE. SSRIs such as sertraline are prescription-only medicines but are not controlled substances under DHA's framework, so they do not require a special-permit prescription process. Ask your GP or insurance provider to refer you to a DHA-licensed psychiatrist who has experience in perinatal mental health.
Coverage varies significantly by insurer and plan tier. Dubai's mandatory basic health insurance (the standard employer-sponsored plan) typically includes some outpatient mental health cover, but sub-limits and prior-authorisation requirements differ between providers. Therapy sessions with a licensed psychologist are covered under many enhanced plans. Medication prescribed by a DHA-licensed psychiatrist is generally claimable under outpatient pharmaceutical benefits. Contact your insurer directly to ask about your annual mental health outpatient sub-limit, whether a GP referral is required to access benefits, and whether your plan covers sessions with a clinical psychologist as a separate line item from a psychiatrist.
Sources and Further Reading
- A Scoping Review of Perinatal Mental Health in the United Arab EmiratesEuropean Journal of Midwifery (2024)
- Perinatal Mental HealthWorld Health Organization (2024)
- Using SSRI Antidepressants During BreastfeedingNHS Specialist Pharmacy Service (2024)
- A Systematic Review of Antidepressants and Breastfeeding: Infant Exposure, Clinical Outcomes, and GuidelinesUguz (published via PubMed, 2021 meta-analysis)
- Postnatal Depression and Infant Development: A Systematic ReviewPMC (2005)
- Breastfeeding and Postpartum Depressive Symptoms: UAE Cohort StudyPMC (2023)